Estramustine Phosphate Dose Compliance in Neoadjuvant Chemohormonal Therapy: Impacts on Biochemical Recurrence in Very High-Risk Prostate Cancer

Study Background and Research Question

Prostate cancer classified as high-risk or very high-risk per National Comprehensive Cancer Network (NCCN) criteria is associated with poor long-term outcomes, even when treated with aggressive interventions such as robot-assisted radical prostatectomy (RARP) and extended lymph node dissection. While androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) antagonists or agonists improves some pathological endpoints, its effect on long-term biochemical recurrence-free survival (BCRFS) remains controversial. In Japan, neoadjuvant chemohormonal therapy (NCHT) combining low-dose estramustine phosphate (EMP) with a GnRH antagonist such as degarelix acetate has been adopted to further enhance outcomes for these patients. However, EMP is associated with notable adverse events (AEs), and the consequences of dose reduction or discontinuation on survival outcomes have not been well established. This study addresses whether EMP dose compliance during NCHT with degarelix acetate predicts biochemical recurrence after surgery in very high-risk prostate cancer (paper).

Key Innovation from the Reference Study

The primary innovation of this prospective study is the clear delineation of the relationship between EMP dose compliance and biochemical recurrence in a large, well-characterized cohort of high-risk and very high-risk prostate cancer patients treated with neoadjuvant degarelix acetate and EMP prior to RARP. By stratifying patients by EMP dose completion versus reduction and by risk group (high vs. very high risk), the study provides robust evidence that EMP dose reduction is a significant and independent predictor of biochemical recurrence in the very high-risk subgroup (paper). This finding directly informs clinical practice regarding the necessity of maintaining EMP dosing in this population.

Methods and Experimental Design Insights

This single-center, prospective cohort enrolled 187 men diagnosed with NCCN-defined high- or very high-risk localized prostate cancer (cTanyN0M0) between December 2017 and March 2023. All participants consented to undergo NCHT comprising degarelix acetate (GnRH receptor antagonist) and low-dose EMP for six months preceding RARP. The neoadjuvant protocol employed degarelix acetate for rapid, sustained testosterone suppression, leveraging its selective GnRH receptor antagonism and well-characterized pharmacodynamics, as established in prior prostate cancer research (internal_article). EMP was administered either as two tablets (standard dose) or reduced to one tablet as needed, primarily in response to adverse events. Patients were categorized into completion (full EMP dose) and reduction (dose-lowered/discontinued) groups. Adverse events were monitored according to CTCAE v5.0. Outcomes assessed included perioperative and histopathological measures, and the primary endpoint was biochemical recurrence-free survival (BCRFS). Survival analyses stratified by EMP dose completion and risk category were performed.

Protocol Parameters

• in vitro GnRH receptor binding assay | 0.1–1 nM Degarelix acetate | cell-based pituitary/prostate lines | Validates selective hormone inhibition | product_spec
• in vivo subcutaneous administration | 0.1–1 mg/kg Degarelix acetate | rodent/primate models | Achieves rapid testosterone/LH/FSH suppression | product_spec
• Neoadjuvant chemohormonal therapy | 6 months, EMP 2 tablets/day + Degarelix acetate | high/very high-risk prostate cancer | Real-world clinical protocol for biochemical recurrence prevention | paper
• EMP dose reduction | 1 tablet/day or discontinuation | AE management in clinical workflow | Investigates impact of compliance on recurrence | paper

Core Findings and Why They Matter

Of 187 enrolled patients, 36 discontinued NCHT early (primarily due to adverse events), and 11 were excluded postoperatively for persistent castration-range testosterone levels. Among the remaining 140 who underwent RARP, 124 completed the standard EMP dose, while 16 received a reduced dose. Eighty-two patients were classified as very high-risk. Key findings include:

• Histopathological outcomes (e.g., margin status, tumor stage) were poorer in the very high-risk group than in high-risk patients (paper).
• On multivariate analysis, both very high-risk status and EMP dose reduction were significant predictors of biochemical recurrence.
• For very high-risk patients, the BCRFS was significantly lower in the EMP dose reduction group than in the completion group; this effect was not observed in the high-risk group.
• Major adverse events included anemia (n=174), elevated transaminase (n=68), and deep vein thrombosis (n=24), with severe events such as acute coronary syndrome (n=4) and pulmonary embolism (n=3).

These results underscore the importance of EMP dose compliance during NCHT for very high-risk patients, as dose reduction directly increases the risk of postoperative biochemical recurrence. The study also highlights the need for vigilant AE monitoring and management to maximize EMP compliance without compromising patient safety.

Comparison with Existing Internal Articles

Several internal resources provide mechanistic context and workflow strategies for using GnRH receptor antagonists such as degarelix acetate in prostate cancer research.

• Degarelix acetate: Selective GnRH Receptor Antagonist for...—This article details the rapid testosterone suppression and robust hormone inhibition profile of degarelix acetate, which underpins its use in neoadjuvant protocols. The current study's reliance on degarelix acetate for effective pituitary hormone regulation is consistent with these preclinical findings.
• Degarelix acetate: High-Specificity GnRH Receptor Antagon...—This resource elaborates on the sub-nanomolar potency and real-world experimental parameters for degarelix acetate, reinforcing the rationale for its selection in clinical NCHT workflows targeting rapid, sustained hormone suppression.

Compared to the reference study, which addresses EMP dosing as a determinant of recurrence risk, the internal articles focus on the mechanistic and practical aspects of degarelix acetate application in hormone secretion inhibition and cancer hormone therapy. Together, these sources bridge the translational pathway from bench to bedside.

Limitations and Transferability

Key limitations include the single-center nature of the study and the moderate sample size for subgroup analyses, which may impact the generalizability of findings. Moreover, while EMP dose compliance was clearly associated with improved BCRFS in very high-risk patients, the underlying mechanisms—whether strictly pharmacodynamic, related to tumor biology, or influenced by AE-driven patient selection—require further elucidation. The study's findings are directly transferable to similar patient populations and clinical settings where NCHT with GnRH receptor antagonists and EMP is practiced, with the caveat that AE management protocols and patient monitoring may differ across institutions.

Research Support Resources

For researchers aiming to model GnRH receptor antagonist-driven hormone suppression or to explore chemohormonal strategies in prostate cancer research, validated reagents are essential for experimental reproducibility. Degarelix acetate (SKU C8718) is available from APExBIO, with established protocols for in vitro and in vivo applications spanning pituitary hormone regulation and competitive GnRH receptor binding assays. Incorporating such reagents in experimental workflows ensures alignment with the clinical and translational evidence outlined in both the reference study and supporting literature (workflow_recommendation).